Charles N. York II Sells 4,282 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Charles N. York II sold 4,282 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $6.26, for a total transaction of $26,805.32. Following the transaction, the chief financial officer now owns 265,231 shares of the company’s stock, valued at $1,660,346.06. The trade was a 1.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Day One Biopharmaceuticals Stock Up 1.5%

Shares of NASDAQ DAWN opened at $6.58 on Wednesday. Day One Biopharmaceuticals, Inc. has a twelve month low of $6.08 and a twelve month high of $16.76. The firm has a market cap of $666.96 million, a P/E ratio of -6.39 and a beta of -1.24. The company has a 50 day moving average of $7.36 and a 200 day moving average of $10.68.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its earnings results on Tuesday, May 6th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.11. The company had revenue of $30.76 million for the quarter, compared to analysts’ expectations of $30.28 million. As a group, equities analysts expect that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

DAWN has been the subject of several recent research reports. Needham & Company LLC lowered their target price on shares of Day One Biopharmaceuticals from $30.00 to $27.00 and set a “buy” rating for the company in a report on Wednesday, May 7th. JPMorgan Chase & Co. decreased their price objective on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating for the company in a report on Wednesday, March 5th. HC Wainwright restated a “buy” rating and issued a $36.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, April 3rd. Wedbush restated an “outperform” rating and issued a $25.00 price objective on shares of Day One Biopharmaceuticals in a report on Wednesday, May 7th. Finally, The Goldman Sachs Group decreased their price objective on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a “buy” rating for the company in a report on Tuesday, March 25th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Day One Biopharmaceuticals currently has an average rating of “Buy” and an average target price of $30.57.

Institutional Investors Weigh In On Day One Biopharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in DAWN. GF Fund Management CO. LTD. purchased a new stake in Day One Biopharmaceuticals during the 4th quarter valued at $27,000. R Squared Ltd purchased a new stake in Day One Biopharmaceuticals during the 4th quarter valued at $31,000. Quantbot Technologies LP purchased a new stake in Day One Biopharmaceuticals during the 1st quarter valued at $82,000. Pallas Capital Advisors LLC purchased a new stake in Day One Biopharmaceuticals during the 1st quarter valued at $87,000. Finally, Wealth Enhancement Advisory Services LLC purchased a new stake in Day One Biopharmaceuticals during the 1st quarter valued at $88,000. 87.95% of the stock is currently owned by hedge funds and other institutional investors.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.